Product image of Zolgensma (Onasemnogene Abeparvovec) supplied by GNH India

Zolgensma

Active Ingredient:
Onasemnogene Abeparvovec
Origin:
EU

Zolgensma (Onasemnogene Abeparvovec)

Zolgensma (onasemnogene abeparvovec) is a gene therapy for spinal muscular atrophy (SMA) in pediatric patients. Administered via a single intravenous infusion, it replaces the missing or faulty SMN1 gene. This overview covers uses, effects, and handling notes for informational purposes only.

Manufacturer / TM Owner

Novartis Europharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Zolgensma is used to treat spinal muscular atrophy (SMA), a genetic disorder affecting motor neurons and muscle function. It is indicated for pediatric patients with SMA Type 1 or those with up to three copies of the SMN2 gene. The therapy aims to improve motor function and survival by delivering a functional copy of the SMN1 gene. It is not a cure but targets the root cause of SMA.

Side Effects

  • After administration, Zolgensma works by introducing a working copy of the SMN1 gene into cells, which may help slow the progression of SMA symptoms. Patients may experience improved muscle strength and motor skills over time, though individual responses vary. Some children show early gains in developmental milestones, such as sitting or standing, while others may see stabilization of their condition.

Precautions & Warnings

  • Zolgensma is administered in a clinical setting by healthcare professionals due to the need for careful monitoring. Patients should be evaluated for liver function before and after treatment, as elevated liver enzymes may occur. Close follow-up is required to assess response and manage any potential side effects. Avoid live vaccines for several weeks before and after treatment.

Avoid Interactions

  • Zolgensma may interact with medications that affect liver enzymes, such as certain anticonvulsants or corticosteroids, potentially altering its effectiveness. Immunosuppressants could impact the immune response to the gene therapy. Always inform healthcare providers about all medications, supplements, or herbal products being used. No specific drug interactions have been definitively established.

Frequently Asked Questions

Zolgensma is a gene therapy used to treat spinal muscular atrophy (SMA) in pediatric patients by replacing the missing SMN1 gene.

It is given as a single intravenous infusion in a clinical setting by healthcare professionals.

Zolgensma targets the root cause of SMA but is not a cure; it aims to improve symptoms and slow progression.

Common effects may include elevated liver enzymes and potential immune responses, requiring monitoring.

It is indicated for specific SMA types and patient profiles; eligibility is determined by healthcare providers.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Onasemnogene Abeparvovec

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT